Infliximab not biosimil 10mg
Products billed under this code include Infliximab, Remicade.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Infliximab, Remicade.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Infliximab | Janssen Biotech, Inc. | 57894-0160-01 | 10 | $298.56 |
| Remicade | Janssen Biotech, Inc. | 57894-0030-01 | 10 | $298.56 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $29.856 | −$1.623 | 10 MG | Infliximab not biosimil 10mg | v1, posted September 17, 2026 |
| 3Q26 | $31.479 | +$0.438 | 10 MG | Infliximab not biosimil 10mg | v1, posted September 15, 2026 |
| 2Q26 | $31.041 | −$1.382 | 10 MG | Infliximab not biosimil 10mg | v1, posted September 15, 2026 |
| 1Q26 | $32.423 | +$1.333 | 10 MG | Infliximab not biosimil 10mg | v1, posted September 15, 2026 |
| 4Q25 | $31.09 | −$0.089 | 10 MG | Infliximab not biosimil 10mg | v1, posted September 8, 2026 |
| 3Q25 | $31.179 | +$0.656 | 10 MG | Infliximab not biosimil 10mg | v1, posted March 10, 2026 |
| 2Q25 | $30.523 | −$0.002 | 10 MG | Infliximab not biosimil 10mg | v1, posted March 10, 2026 |
| 1Q25 | $30.525 | −$1.698 | 10 MG | Infliximab not biosimil 10mg | v1, posted December 19, 2025 |
| 4Q24 | $32.223 | +$0.516 | 10 MG | Infliximab not biosimil 10mg | v1, posted June 11, 2025 |
| 3Q24 | $31.707 | +$0.036 | 10 MG | Infliximab not biosimil 10mg | v1, posted June 11, 2025 |
| 2Q24 | $31.671 | −$0.49 | 10 MG | Infliximab not biosimil 10mg | v1, posted March 11, 2025 |
| 1Q24 | $32.161 | −$0.476 | 10 MG | Infliximab not biosimil 10mg | v1, posted December 19, 2024 |
| 4Q23 | $32.637 | −$0.27 | 10 MG | Infliximab not biosimil 10mg | v1, posted October 10, 2024 |
| 3Q23 | $32.907 | −$1.136 | 10 MG | Infliximab not biosimil 10mg | v1, posted June 5, 2024 |
| 2Q23 | $34.043 | −$0.819 | 10 MG | Infliximab not biosimil 10mg | v1, posted February 23, 2024 |
| 1Q23 | $34.862 | −$0.16 | 10 MG | Infliximab not biosimil 10mg | v1, posted December 6, 2023 |
| 4Q22 | $35.022 | −$0.691 | 10 MG | Infliximab not biosimil 10mg | v1, posted June 22, 2023 |
| 3Q22 | $35.713 | −$0.80 | 10 MG | Infliximab not biosimil 10mg | v1, posted June 9, 2023 |
| 2Q22 | $36.513 | −$1.169 | 10 MG | Infliximab not biosimil 10mg | v1, posted December 14, 2022 |
| 1Q22 | $37.682 | −$1.85 | 10 MG | Infliximab not biosimil 10mg | v1, posted June 8, 2022 |
| 4Q21 | $39.532 | −$1.787 | 10 MG | Infliximab not biosimil 10mg | v1, posted June 2, 2022 |
| 3Q21 | $41.319 | −$0.633 | 10 MG | Infliximab not biosimil 10mg | v1, posted June 2, 2022 |
| 2Q21 | $41.952 | −$2.95 | 10 MG | Infliximab not biosimil 10mg | v1, posted March 1, 2022 |
| 1Q21 | $44.902 | – | 10 MG | Infliximab not biosimil 10mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.